Milvexian

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

137 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

1

Milvexian

Johnson & Johnson

Phase 3

12

Calquence

AstraZeneca

Preclinical

13

Rituxan

Roche

Preclinical

—4

Coumadin

AAbbott

Preclinical

35

Brukinsa

BBeOne Medicines

Preclinical

16

Imbruvica

PPharmacyclics LLC.

Preclinical

17

Versed

CConrado Roberto Hoffmann Filho

Preclinical

18

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

19

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

110

Statin

Bristol-Myers Squibb

Preclinical

1Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Atorvastatin1 trial

A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

Completed·Johnson & Johnson·Phase 1·NCT04388501·23 enrolled

Anticoagulant1 trial

A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

Completed·Johnson & Johnson·Phase 1·NCT04543383·52 enrolled

Female1 trial

A Study of Milvexian in Healthy Adult Females

Completed·Johnson & Johnson·Phase 1·NCT05706753·20 enrolled

Adult1 trial

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Completed·Johnson & Johnson·Phase 1·NCT04844424·115 enrolled

Ischemic Stroke; Ischemic Attack, Transient1 trial

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Active, not recruiting·Johnson & Johnson·Phase 3·NCT05702034·12,523 enrolled

2 more indications

Atrial Fibrillation1 trial

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation

Active, not recruiting·Johnson & Johnson·Phase 3·NCT05757869·20,284 enrolled

Acute Coronary Syndrome1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome

Completed·Johnson & Johnson·Phase 3·NCT05754957·14,194 enrolled

Details

Drug Info

Related News